Phase 2 biotech developing oral treatments for hypertension and cardio-renal diseases.
Industry: Health Care
Latest Trade: $29.06 0.00 (0.0%)
First Day Return: 0.0%
Return from IPO: +81.6%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 12/17/2021 |
Offer Price | $16.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 12.1 |
Deal Size ($mm) | $194 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 01/06/2022 |
Offer Price | $16.00 |
Price Range $15.00 - $17.00 | |
Offer Shares (mm) | 12.1 |
Deal Size ($mm) | $194 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
Underwriters |
---|
Morgan Stanley |
Jefferies |
more |
Company Data | |
---|---|
Headquarters | Boston, MA, United States |
Founded | 2018 |
Employees at IPO | 10 |
Website www.cincor.com |